GlaxoSmithKline sets $1.6B in new cost cuts, thanks in part to Advair's U.S. formulary discounts

Brace yourselves for layoffs at GlaxoSmithKline ($GSK). The saga is familiar: An aging blockbuster loses steam to competing meds, and its maker gets out the cost-cutting ax to compensate. This time, the faltering drug is Advair, which adds some new twists to the story--including a warning to the whole pharma industry about formulary placement. Report

Suggested Articles

Enhertu cut the risk of death by 41% compared with chemo in previously treated HER2-positive gastric cancer.

CanSino reports positive data for COVID-19 vaccine. Takeda's Alunbrig wins first-line lung cancer nod. GSK inks $231 million deal with Samsung.

Gilead is working to move CAR-T med Yescarta into other types of NHL, and if data from an interim trial look-in are any indication, it's on its way.